Tianyan Zhou[Author] - Search Results

Year	Number of Results
2003	1
2004	1
2006	1
2007	1
2008	5
2009	3
2010	2
2011	6
2012	10
2013	9
2014	12
2015	12
2016	8
2017	9
2018	4
2019	7
2020	12
2021	2
2022	7
2023	3
2024	1

1

Disease progression model of 4T1 metastatic breast cancer.

Yang L, Yong L, Zhu X, Feng Y, Fu Y, Kong D, Lu W, Zhou TY. Yang L, et al. J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):105-116. doi: 10.1007/s10928-020-09673-5. Epub 2020 Jan 22. J Pharmacokinet Pharmacodyn. 2020. PMID: 31970615

2

Breast cancer treatment and sulfotransferase.

Ji XW, Zhou TY, Lu Y, Wei MJ, Lu W, Cho WC. Ji XW, et al. Expert Opin Ther Targets. 2015 Jun;19(6):821-34. doi: 10.1517/14728222.2015.1014803. Epub 2015 Feb 12. Expert Opin Ther Targets. 2015. PMID: 25677121 Review.

3

Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy.

Song L, Cui C, Zhou Y, Dong Z, Yu Z, Xu Y, Zhou T, Abduljalil K, Han H, Li L, Yang J, Zhao Y, Li H, Liu D. Song L, et al. Among authors: zhou t. Curr Drug Metab. 2020;21(9):722-741. doi: 10.2174/1389200221666200907143941. Curr Drug Metab. 2020. PMID: 32895038 Review.

4

Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.

Song L, Xue J, Zhang J, Li S, Liu D, Zhou T. Song L, et al. Among authors: zhou t. Eur J Pharm Sci. 2021 Mar 1;158:105584. doi: 10.1016/j.ejps.2020.105584. Epub 2020 Oct 9. Eur J Pharm Sci. 2021. PMID: 33039565 Review.

5

Urea-containing peptide boronic acids as potent proteasome inhibitors.

Han LQ, Yuan X, Wu XY, Li RD, Xu B, Cheng Q, Liu ZM, Zhou TY, An HY, Wang X, Cheng TM, Ge ZM, Cui JR, Li RT. Han LQ, et al. Eur J Med Chem. 2017 Jan 5;125:925-939. doi: 10.1016/j.ejmech.2016.10.023. Epub 2016 Oct 14. Eur J Med Chem. 2017. PMID: 27769033

6

A model-based meta-analysis of immune-related adverse events during immune checkpoint inhibitors treatment for NSCLC.

Zhang R, Kong D, Chen R, Guo Y, Jian W, Han M, Zhou T. Zhang R, et al. Among authors: zhou t. CPT Pharmacometrics Syst Pharmacol. 2022 Aug;11(8):1135-1146. doi: 10.1002/psp4.12834. Epub 2022 Jul 4. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35763678 Free PMC article.

7

[Population pharmacokinetics and its application in new drug research].

Chen WJ, Zhou TY, Lu W. Chen WJ, et al. Yao Xue Xue Bao. 2017 Mar;52(3):371-7. Yao Xue Xue Bao. 2017. PMID: 29979556 Review. Chinese.

8

Author Correction: QAP14 suppresses stemness and metastasis of breast cancer via the activation of dopamine D1 receptor.

Yong L, Yao Y, Chen GS, Yan XX, Guo YC, Han MY, Xue JS, Jian WZ, Zhou TY. Yong L, et al. Acta Pharmacol Sin. 2022 Jul;43(7):1882-1883. doi: 10.1038/s41401-022-00869-8. Acta Pharmacol Sin. 2022. PMID: 35082395 Free PMC article. No abstract available.

9

Longitudinal and time-to-event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma.

Yao Y, Wang Z, Yong L, Yao Q, Tian X, Wang T, Yang Q, Hao C, Zhou T. Yao Y, et al. Among authors: zhou t. CPT Pharmacometrics Syst Pharmacol. 2022 Sep;11(9):1170-1182. doi: 10.1002/psp4.12835. Epub 2022 Jul 4. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35758865 Free PMC article.

10

Population pharmacokinetics of vancomycin in Chinese pediatric patients .

Liu T, Deng C, Cheng D, Zhou T, Lu H, Wei W, Lu W. Liu T, et al. Among authors: zhou t. Int J Clin Pharmacol Ther. 2017 Jun;55(6):509-516. doi: 10.5414/CP202835. Int J Clin Pharmacol Ther. 2017. PMID: 28257285

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

94 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Results by year